Fleury (FLRY3.SA) Azione Prezzo
Fleury Prezzo
Negli ultimi 19 anni Fleury ha aumentato il fatturato del 16,1% all'anno, raggiungendo 8,29 miliardi BRL. L'utile per azione è cresciuto del 12,5% all'anno negli ultimi 19 anni. Per Fleury, il margine netto del 7,4% risulta in calo rispetto al 9,0% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 6,10%. Il payout ratio è pari a circa il 149% degli utili. Il dividendo è cresciuto del 20,5% all'anno negli ultimi 15 anni. Il target di prezzo di consenso a 12 mesi per Fleury è 18,36 BRL, circa il 33,2% sotto il prezzo attuale di mercato. Su 19 analisti, 11 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Fleury Prezzo delle azioni
Fleury Azione e analisi azionaria
Domande frequenti sull'azione Fleury
The business model of Fleury SA, a leading medical diagnostics company in Brazil, revolves around providing high-quality healthcare services through its network of diagnostic imaging, clinical analysis, and other medical services. Fleury SA aims to ensure accurate diagnoses, offer timely access to medical procedures, and deliver exceptional customer experience. By investing in advanced technology, top-notch professionals, and continuous innovation, Fleury SA effectively meets the healthcare needs of patients across the country. With its strong reputation and diverse range of diagnostic services, Fleury SA strives to maintain its position as a market leader in Brazil's healthcare industry.
Fleury SA is primarily active in the healthcare industry.
The main competitors of Fleury SA in the market include Grupo Fleury, DASA, and Hermes Pardini.
Fleury SA is a leading healthcare company based in Brazil. With a rich history dating back to 1926, Fleury has continually evolved and expanded its operations to become one of the most reputable diagnostic medicine providers in the country. Over the years, the company has developed a strong reputation for its advanced diagnostic techniques and high-quality services, encompassing radiology, pathology, and clinical analysis. With a strong focus on technological innovation, Fleury has consistently invested in cutting-edge equipment and research, enabling them to deliver accurate and reliable results to patients. Today, Fleury SA stands as a trusted name in the healthcare industry, providing comprehensive diagnostic solutions to improve patient outcomes.
Fleury SA, a renowned company, has achieved remarkable milestones throughout its history. Having established a strong presence in the healthcare sector, Fleury SA continuously strives for excellence. Some significant achievements include expanding its network and becoming one of the largest healthcare providers in Brazil. Additionally, Fleury SA has consistently prioritized innovation, implementing advanced technology and processes to deliver high-quality diagnostics and medical solutions. The company's commitment to patient-centric care and a strong focus on research & development have further solidified its position as a trusted leader in the industry. Fleury SA's relentless pursuit of growth and unwavering dedication to improving healthcare services have contributed to its notable achievements.
Fleury SA is primarily present in Brazil, where it operates a wide network of diagnostic medicine and healthcare facilities. With its headquarters in São Paulo, the company is a leader in medical laboratory services, operating in several states across the country. Fleury SA's commitment to providing high-quality diagnostic services has allowed it to expand its presence to other regions of Brazil, catering to a diverse range of patients and medical professionals.
Fleury SA represents a strong set of values and corporate philosophy. With a focus on excellence and innovation, the company strives to deliver the highest quality healthcare services to patients. Fleury SA is committed to providing accurate diagnoses, personalized care, and cutting-edge medical technology. Through continuous improvement, the company aims to surpass industry standards and meet the evolving needs of its customers. With a reputation for professionalism and integrity, Fleury SA upholds a patient-centric approach, putting the well-being and satisfaction of individuals at the forefront. By encompassing these values, Fleury SA remains a trusted leader in the healthcare industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 17,77 BRL per l’azione Fleury (mediana: 18,36 BRL), pari a -35,3 % rispetto all’ultimo prezzo. Il consenso si basa su 19 giudizi di analisti.
18 analisti valutano attualmente l’azione Fleury: 11 raccomandano l’acquisto, 5 la tenuta e 2 la vendita. Per il 2026 gli analisti si aspettano per Fleury ricavi pari a 9,27 miliardi BRL e un utile per azione di 1,46 BRL.
Convertita al tasso di cambio attuale, l’azione Fleury quota 4,91 EUR (27,47 BRL).
L’azione Fleury (FLRY3.SA) è quotata su 2 borse, tra cui: B3 (São Paulo) (FLRY3.SA).
Fleury SA is a company specializing in medical diagnostics and health services. Founded in 1926, the company is headquartered in Sao Paulo, Brazil. With over 9,000 employees and a revenue of more than 2.2 billion Brazilian Reals, Fleury SA is one of the largest medical service companies in South America. The business model of Fleury SA is based on three core areas: diagnostics, health services, and research and development. In diagnostics, the company enables disease identification and offers comprehensive diagnostic solutions. The portfolio of diagnostic services is very broad and includes imaging and radiological diagnostics, laboratory and pathology services, genetic testing, and screening for pregnancy-related diseases. In the field of health services, Fleury SA offers a wide range of services for individuals and companies looking to improve prevention, wellness, and quality of life. The services range from health counseling and health programs to outpatient surgery and rehabilitation facilities. In research and development, the company is interested in driving innovation in the fields of medical diagnostics and health services. Fleury SA invests heavily in the development of new technologies and solutions to improve the accuracy and efficiency of its diagnostic services, as well as in collaboration with academic institutions and other companies. The company is known for adhering to very high quality standards in all aspects of its services. Fleury SA is ISO 9001 certified and is committed to continuously working towards customer satisfaction and process optimization. The company is proud to offer state-of-the-art technology and top-notch medical professionals to provide customers with the best possible service. In addition to its business areas, Fleury SA also offers a variety of products, such as diagnostic instruments and consumables for medical professionals, medical software, and health products for the general public. The products are designed to meet the needs of medical professionals and private consumers and meet the highest quality standards. Overall, Fleury SA has an impressive track record in the field of medical diagnostics and health services. The company has established itself as a trusted provider of high-quality and innovative solutions over the past decades and is committed to continuing to lead the industry with excellence and groundbreaking innovations.
Il attesa fatturato di Fleury ammonta a 9,27 miliardi BRL. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Fleury ammonta a 798,12 Mio. BRL. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Fleury è attualmente 18,76. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Fleury.
Il rapporto prezzo/fatturato (P/S) di Fleury è attualmente 1,62. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Fleury.
Il Quality Score AlleAktien per Fleury è 8/10.
L'ISIN di Fleury è BRFLRYACNOR5. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di Fleury è FLRY3.SA. Con questo simbolo di borsa vengono negoziate le azioni Fleury in borsa.
Azione Fleury
Gruppo di pari di Fleury
Fleury Ticker
Fleury FIGI
Altre metriche e analisi di Fleury in Deep Dive.
La nostra analisi azionaria dell'azione Fleury include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Fleury. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: